Repligen Price to Free Cash Flow Ratio 2010-2024 | RGEN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Repligen average price to free cash flow ratio for 2024 was 72.31, a 31.13% decline from 2023.
Repligen average price to free cash flow ratio for 2023 was 104.99, a 45.71% decline from 2022.
Repligen average price to free cash flow ratio for 2022 was 193.4, a 44.81% decline from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Repligen average price to free cash flow ratio for 2024 was 72.31, a 31.13% decline from 2023.
Repligen average price to free cash flow ratio for 2023 was 104.99, a 45.71% decline from 2022.
Repligen average price to free cash flow ratio for 2022 was 193.4, a 44.81% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$141B
Bristol Myers Squibb (BMY)	$113.2B
Gilead Sciences (GILD)	$112B
Vertex Pharmaceuticals (VRTX)	$105.5B
CSL (CSLLY)	$84.4B
Regeneron Pharmaceuticals (REGN)	$76.6B
GSK (GSK)	$68.6B
Argenex SE (ARGX)	$39.6B
Alnylam Pharmaceuticals (ALNY)	$30.7B
BioNTech SE (BNTX)	$29.5B
Biogen (BIIB)	$21.7B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$17.3B
Moderna (MRNA)	$16.3B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.7B
Incyte (INCY)	$13.6B
BioMarin Pharmaceutical (BMRN)	$12.8B
Sarepta Therapeutics (SRPT)	$11.9B
Insmed (INSM)	$11.7B
Bio-Techne Corp (TECH)	$11.6B
Exact Sciences (EXAS)	$10.5B
Exelixis (EXEL)	$10.3B
QIAGEN (QGEN)	$10.2B
Vaxcyte (PCVX)	$10.1B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Intra-Cellular Therapies (ITCI)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.5B
Ascendis Pharma (ASND)	$7.8B
Roivant Sciences (ROIV)	$7.7B